AD-2021
- Generic Name
- AD-2021
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
Phase 3
Completed
- Conditions
- Hypertension, EssentialPrimary Hypercholesterolemia
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT06448962
- Locations
- 🇰🇷
Yonsei Cardiovascular Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath